ClinicalTrials.gg
CompletedNCT04295161Updated Mar 4, 2020

A Study Designed to Evaluate the Pharmacokinetic Profile of Abiraterone

A Phase 1 interventional study of Abiraterone Acetate in Pharmacokinetics, sponsored by Zentiva, k.s.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Zentiva, k.s. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jun 2019, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A Study in Healthy Male Subjects Designed to Evaluate the Pharmacokinetic Profile of Abiraterone Following Administration of Immediate Release Formulations

Read the detailed description

This was a single centre, 2 part, open-label study in healthy male subjects. Parts 1 and 2 were conducted in separate cohorts of subjects; subjects were not permitted to participate in both parts. Part 1 was a part-randomised, 4 period crossover study planned to include 24 healthy male subjects. Part 2 was a randomised 2-period crossover study in 12 healthy male subjects. The aim was to evaluate the pharmacokinetic profiles of abiraterone following administration of immediate release prototype formulations in healthy male subjects.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Zentiva, k.s. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males
  2. Age 18 to 55 years of age at the time of signing
  3. Expressed a desire not to father children in the near future (within 6 months of last IMP dose); males under 40 years of age must have been vasectomised
  4. (BMI) of 18.5 to 30.0 kg/m2 as measured at screening
  5. Willing and able to communicate and participate in the whole study
  6. Provided written informed consent
  7. Agreed to adhere to the requirements defined in Section 9.4 of the protocol

Exclusion criteria

Exclusion Criteria:

  1. Subjects who received any IMP in a clinical research study within the 3 months or 90 days prior to Day 1 Period 1
  2. Males with a pregnant female partner
  3. Subjects were unable or unwilling to consume the standard high-fat breakfast (Part 2)
  4. Subjects were study site employees, or immediate family members of a study site or sponsor employee
  5. Subjects who had previously been enrolled in this study. Subjects who had taken part in Part 1 were not permitted to take part in Part 2
  6. History of any drug or alcohol abuse in the past 2 years prior to screening
  7. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type) as confirmed by a repeat of the first positive alcohol breath test at screening or admission
  8. Current smokers and those who had smoked within the last 12 months. A confirmed breath carbon monoxide (CO) reading of greater than 10 ppm, as confirmed by repeat of the first test at screening or admission
  9. Current users of e-cigarettes and nicotine replacement products and those who had used these products within the last 12 months prior to screening
  10. Subjects without suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
  11. abnormal biochemistry, haematology or urinalysis at screening as judged by the investigator
  12. Serum potassium below the lower limit of the laboratory reference range at screening
  13. >1.5× upper limit of laboratory reference range at screening
  14. Total >1.5× upper limit of laboratory reference range at screening
  15. Confirmed positive drugs of abuse test result
  16. Positive surface antigen (HBsAg), virus antibody (HCV Ab) orhuman immunodeficiency virus () results at screening
  17. Systolic blood pressure (BP) >140 mmHg, diastolic blood pressure >90 mmHg (systolic blood pressure up to 150 mmHg allowed in subjects >45 years of age) at screening or Period 1 Day 1 pre-dose
  18. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
  19. Subjects with a history of cholecystectomy or gall stones
  20. Serious adverse reaction or serious to any drug
  21. History of any hypersensitivity reaction to abiraterone or the formulation regardless of severity
  22. Subjects with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, lactose intolerance
  23. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever was allowed unless it was active
  24. Donation or loss of greater than 400 mL of blood within the previous 3 months prior to screening
  25. Subjects who were taking, or had taken, any prescribed or over-the-counter drug (other than 4 g of paracetamol per day) or herbal remedies in the 14 days before Day 1, Period 1. Exceptions may have been applied on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI
  26. Use of known strong inducers, including St John's Wort, in the 30 days prior to Period 1 Day 1
  27. Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    Reference

    Drug: Abiraterone Acetate

  • Experimental
    Prototype 1

    Drug: Abiraterone Acetate

  • Experimental
    Prototype 2

    Drug: Abiraterone Acetate

  • Experimental
    Prototype 3

    Drug: Abiraterone Acetate

  • Experimental
    Prototype 4 fasted

    administered in fasted state

    Drug: Abiraterone Acetate

  • Experimental
    Prototype 4 fed

    Administered in fed state

    Drug: Abiraterone Acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Abiraterone Cmax

    maximal concentration of abiraterone in human plasma

    Time frame: 24h

  2. Abiraterone AUC

    total exposure up to 24h of abiraterone in human plasma

    Time frame: 24h

07

Study locations

1 site
  • Quotient Sciences
    Ruddington, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Nov 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 4, 2020
StartActual
Jun 25, 2019
Primary completionActual
Nov 8, 2019
CompletionActual
Nov 8, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04295161
Lead sponsor
Zentiva, k.s.
Responsible party
Sponsor
First posted
Mar 4, 2020
Start date
Jun 25, 2019
Primary completion
Nov 8, 2019
Completion
Nov 8, 2019
Last update
Mar 4, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion